In short
CNBC's "Fast Money" Episode Summary - Apple’s Record High… And Structure Therapeutics’ CEO On Weight Loss Drugs (6/11/24)
Episode Overview This episode of CNBC's "Fast Money," hosted by Melissa Lee, features discussions on Apple's remarkable stock performance following a recent AI announcement, the competitive landscape of weight loss medications, particularly focusing on Structure Therapeutics, and other significant market movements.
---
Key Topics Discussed
- Apple's Stock Performance
- Record Highs: Apple shares surged over 7%, resulting in an increase of $215 billion in market capitalization, placing it just $40 billion shy of reclaiming its title as the most valuable company from Microsoft.
- Previous Concerns: Just a day prior, there were concerns regarding the lackluster response to their AI announcements at the WWDC (Worldwide Developers Conference).
- Analyst Opinions: Diverse opinions emerged regarding whether the announcements would stimulate the iPhone replacement cycle.
- Gene Munster posited it would accelerate the replacement cycle.
- Morgan Stanley echoed optimism, whereas UBS expressed skepticism.
- Structure Therapeutics and the Weight Loss Drug Market
- Current Standing: Structure Therapeutics experienced a temporary pullback but remains up over 20% this year due to advancing trials for its oral GLP-1 obesity drugs.
- CEO Ray Stevens Interview Highlights:
- Scalability: The company has the capability to manufacture enough of its oral GLP-1 product to potentially serve over 100 million patients, significantly exceeding current access.
- Market Potential: The oral formulation is seen as competitive against injectables from major players like Eli Lilly and Novo Nordisk.
- Next Steps: The initiation of a Phase 2B study is planned for Q4 2024, with results expected in late 2025.
- Paramount's Deal with Skydance
- Deal Collapse: Discussions around a deal for Skydance to acquire a controlling stake in Paramount ended abruptly, attributed to non-economic concerns from Paramount's leadership.
- Current Market Position: Paramount is grappling with high debt and leadership instability, raising questions about its future in an evolving media landscape.
- Broader Market Insights
- Tech Sector Performance: The S&P 500 and NASDAQ reached record highs, while the Dow saw a slight decline amid anticipation of the upcoming CPI report and Federal Reserve decisions.
- Investor Sentiment: Discussion centered on the current state of the market, with a notable focus on momentum-driven investments and the implications of Fed policies on market trends.
---
Key Takeaways
- Apple's Recent Surge: Reflects a volatile market reaction to new product announcements and ongoing speculation about its long-term growth potentials, particularly in AI and services.
- Structure Therapeutics' Growth Potential: Highlights the innovation in the pharmaceutical sector, particularly in obesity treatment, with a focus on accessibility and scalability.
- Market Uncertainty: Ongoing concerns about key corporate deals collapsing and the implications of Fed policies introduce caution among investors.
---
Conclusion This episode of "Fast Money" encapsulates the dynamic interplay between tech advancements, market speculation, and the evolving landscape of pharmaceuticals. The discussions provide insights for investors looking to navigate these trends intelligently as they unfold.
Written by AI. May contain mistakes. Listen to the episode to check what was said.
Transcript
Automatic transcript. May contain errors.0:02Live from the Nasdaq market site in the heart of New York City's Times Square. This is fast money. Here's what's on tap tonight. Apple ascending. The tech giant rocketing to new heights. on the heels of its AI reveal yesterday, the massive numbers behind this move and what it says about the strength of the broader markets and shares of Structure Therapeutics pulling back from recent highs, but hopes for its obesity pills still have the stock up more than 20 % this year. We'll talk to the CEO, Ray Stevens, about its latest trial results in a first-on CNBC interview later this hour. Plus, a paramount plunge, its deal with Skydance falling apart.
0:34What caused talks to break down and what's next for the company? David Faber will join us here on set just minutes from now. I'm Melissa Lee. Come to you live from Studio B at the NASDAQ. On the desk tonight, C. Grasso, Karen Feinerman, Dan Nathan, and Guy Adami. And we start off with Apple's astonishing run to new records. The tech giant soaring more than 7 % today, its best day since November 2022. That move adding a whopping$215 billion to its market cap. That is more than one entire Adobe. It is now just$40 billion away from reclaiming the most valuable company title from Microsoft, a position it seeded back in January.
1:10Apple was the top performer in the S &P Dow and the Nasdaq 100, quite a turnaround after leading the Dow lower post yesterday's WWDC kickoff. So what changed for Apple in just the past 24 hours? It was just 24 hours ago, Guy, that we were all sitting here around the desk lamenting how boring the reveal was, how it wouldn't end up selling more phones. And here we are. The whole spiel took you 10 minutes to go through. Well, I mean, I don't need a lot of help looking stupid, as you know, but Apple managed to help me today. And look, I think that I guess the market had a chance to digest certain things.
1:45You know, Gene Munster yesterday put out a very compelling case. And then on Twitter about an hour or so ago, he said the crazy part of the factors driving Apple shares today are just getting started. And maybe he's spot on. He's been spot on. You know, I'll say this, though. I think the upgrade cycle was in place all along. You know, I'm still not convinced that this will add to it. However, the market seems to be maybe on the services size. It gives them that kicker where you get services revenue now closer to 30 percent, which helps their valuation. Right. I get that. But I'll say again, yesterday made sense to me in terms of the sell off.
2:19It had a big volume day. I thought you put in a bit of a double top. That clearly wasn't the case. All right. So yesterday, Gene Munster made a very interesting statement. He said yesterday was the biggest day for Apple since the launch of the iPhone. You pushed back pretty hard. You said, hey, Gene, you want to take that back? I'll give you a chance to take it back. And Gene said, no, I'm not going to take it back. But you clearly disagreed. And I still disagree, despite, you know, a nearly 8 % rise. And listen, you know, Gene, you know, is a great analyst who's been covering this for a very long time.
2:49And, you know, at the end of the day, Apple might have had its biggest market cap gain in its history, too, on the back of this. And, you know, I'm just hard pressed to believe that much of what they reported yesterday or detailed is going to be usable in the next iteration of the iPhone that comes out in September and October. And so if you can justify the sort of move that the stock had today, you really have to be able to think that earnings are going to go up meaningfully, that, you know, from a mid single digit sort of thing and revenues and mid single digits to, you know, and I'm not sure about that.
3:21I mean, so again, I think that investors are getting ahead of the street, meaning Wall Street analysts, because I did not see a bunch of analysts come up and upgrade the stock or raise their calendar 2025 earnings. So again, we are in a market where there seems to be no shortage of enthusiasm for stories that are perceived to work. And then the flip side, you just mentioned Adobe. There's no shortage of downside for the stocks that don't seem to be participating in the excitement around AI. It seems like the bottom line question here is, did Apple reveal something yesterday that will drive more sales of phones than previously modeled in?
3:59Morgan Stanley says, yes, it should accelerate the replacement cycle. UBS says it is unlikely to drive the iPhone replacement cycle. I mean, it's really split here. So accelerate is one thing. Does it create additional? Additional. Right. Additional. So accelerate, maybe. Because everybody thought there was somewhat of an upgrade cycle in place. So the question is, will there be additional incremental consults? No, I actually don't think so. I was kind of underwhelmed as well. The only thing I can imagine is, the only thing that makes sense to me is we used to have a hardware multiple and a software multiple, right?
4:31Now we have a hardware multiple, software multiple, and I guess an AI multiple, which maybe is what, I mean, at 30, I don't know, 31, 32 times, with a reasonable size element of hardware multiple, you've got to have a pretty good multiple on the rest of the business. And I guess that's what it is. I don't know. I have a tiny position that's so small, it's effectively short because I get upset when it goes up by this much. But I don't know. I wasn't so excited by that yesterday, particularly the Siri part. But, you know, I got it in for Siri, but I didn't think that was great. I think Gene's more excited about 2 percent growth going to 10 and 12 percent.
5:09So I think that's what is really moving the needle. And to Guy's point, services, that number will go up. Analysts will chase it at a certain point because they're not known for being first on it. They'll they'll they'll lag. They'll the analysts will lag and then we'll upgrade it as the story develops. I bet you you're going to see, I don't know, next week, week after a bunch of analysts upgrading their their sales numbers, their numbers on upgrade cycle. And they'll chase it. Yeah. But one thing, Mel, I just want to get in it. So the stock now is trading at 31 and a half times this year, 28, nearly 29 times next.
5:46So the fact that earnings estimates did not go up today, commensurate with the seven and a half percent move, makes the stock a lot more expensive. And if they don't continue to go up and listen, I can take out a few positives that I had to actually think about over the last 24 hours. I got to read some really smart people and what they had to say about it. One of the positives that they didn't have to pay for this, it sounds like. So they didn't have to pay open A.I. for this. So that's pretty good. They also said, and they didn't say this during the day, but they said it much later, that they're going to have Anthropics Cloud on there.
6:17And they're going to have Gemini eventually and that sort of thing. So they're going to become an aggregator of what is becoming a very commoditized space, this large language model. So they didn't spend the billions of dollars building out or building these models and training them and the like here. So that is a positive. That's a positive. But when you take a look at some of the other AI sort of beneficiaries, they are monetizing because they are charging. So analysts can model that. For Apple, how do you model something that will be incorporated into apps that will be developed later on? Because it was WWDC.
6:49It was a developers conference yesterday. And so those revenues won't come until later, until after more people have the 15 Pro, until after all these. So this is sort of a delayed increase in services revenue that we're talking about. The market is getting ahead of, I think, exactly what you just outlined. And it's getting ahead of it in a major way. And again, I'll say I think last quarter, and you can check me, but I think we were close to 25 percent of overall revenue was on the services side, which I think may have been a record. It would be nice if we continue to see the revenue growth that was commensurate with the valuation of trades that maybe we'll start to see that.
7:22But if that goes from 25 to 28, 29, then you could probably justify the multiple. But I think that's at the crux of your question. Is it going to show up in the services side of things? And I think they just didn't have to screw it up. I think that's the point is if there was a path, they just had to lay out a path. I mean, how could they? I mean, they had a partnership, right? Yeah, but to Dan's point, a lot of the stuff is they don't really innovate. We've all said this. They don't innovate. They replicate. And people love the iPhone. I have the iPhone 13. I probably will upgrade this cycle because of this.
7:55So is that another buyer? No, but it's getting me off the bubble sooner than I would have otherwise. The sidelines. and it may cause you to upgrade to the highest level phone as opposed to the second highest level phone. But the jury is still out. Okay, so I think about my iPhone. I use Gmail. I use YouTube. I use a whole host of Google products that Gemini is already embedded in. Okay, now that's going to the cloud and what Apple is trying to tell you that a lot of this stuff is going to happen on device. And then if you think about Meta, okay, there's Reels, there's Instagram, and there's WhatsApp.
8:26Their Meta AI is already embedded in that. So a lot of users who are really sticky with those sorts of apps on their iPhone are really not going to use Genmojis and all this other sort. They're just not going to use Genmojis. So think about this, Dan, they're making AI more. I think you're nailing a point in reverse. I think I think that the people that have the iPhone want to use an AI and they're more likely to use Apple's AI versus the other ones that you just named. So I just don't really think so. if you're using these apps, they're not, you know, iOS, they're not from, you're not going to change your behavior.
9:01So the apps that you use. You are a customer Apple has already lost. Yeah. I mean, it's going to be on the thing, but I'm not going to upgrade. And what did I say last night? No one's going to upgrade for this device, given how the staggered release of these products, like that's the other point. They're not all coming out on iOS 18 and it's going to take some time. And the other thing is it's going to be buggy. And you know what I mean? Like, so I just think the euphoria right now just seems to be a little misplaced. Katie Stockton was here the other night and said she would buy Apple higher.
9:27So Apple was in a proving ground on the chart and she would buy higher. This is, I think, past the level which she said she would buy. No, I think she made a great point. I mean, we were having the same conversation about in terms of how the stock traded, traded up to those prior highs. Again, yesterday seemingly failed on what was one and a half, almost two times normal volume. It made sense. She also said, though, if the stock proves itself and breaks out, then she would re-engage. And I think with the volume we saw today, that's exactly what happened. Would you re-engage here? Or would you pay?
9:55No, because again, I think it's still expensive. Look, but I've thought it's been expensive for a while. I'll say this as well, though. Apple's not a straight line higher for the last five or six years. And listen, in April, we saw a stock that went from 198 down to about 165 or so. So you do see drawdowns in the name. I don't really know necessarily what it's predicated upon, but it does happen in Apple from time to time. All right, let's move on to Oracle here. Shares are sharply higher after hours, despite reporting a miss on the top and the bottom line. News of a multi-cloud partnership with Google and OpenAI, the driver of the stocks gains.
10:26The conference call just started at the top of the hour. That's where the company will issue guidance. We'll be keenly listening into that call for the guidance part of it. We're up 9 % in the after-hour session. AI, it's just, it's AI here. Yeah, but again, okay, so cloud infrastructure, which is 15 % of their business, was up dramatically, 40 % year over year. It's$2 billion in the quarter. You know what I mean? So we're not even hitting numbers that are particularly impactful if you think about it. And I think without that headline, the stock is probably trading unchanged and down as we wait for the guidance.
10:58And then I go back and think about Dell and what they had to say. They put up a good quarter and their guidance was disappointing. This is not expensive stock. And so if you think that this is a bit of a laggard in the space, like I think you should continue to expect good news out of this company. But not right here. Not like this. I just thought that remaining performance obligation number was so high. It was so much higher than where the street was that, I mean, that's sort of looking at, all right, doesn't matter what they did this quarter. They're building a huge book of business going forward.
11:29So, I mean, should it be up$10 or$11, whatever it is, I don't know, but it certainly should be up. And they have to prove that they could build those data centers. So how quick are they going to come on to take advantage of that performance that's in the pipeline? And the truth is, when you look at CRM, you look at Workday and you look at MongoDB, they all sold off. So did this one. And this one sort of started bouncing back a lot quicker than the other ones did. So somebody knew they were going to beat on that number. It's a matter of do they beat and do they perform now? It was a quarter that came in at the lower end of what street expectations were in terms of EPS and revenue.
12:09X this AI announcement to Dan's point, the stock, which historically, if you go back over the last year and a half, two years, tops out at about 127 or so. It's been in this 102, 127 range. I think the same thing probably would have happened. However, you put that kicker in there, the machines pick it up. And here we are now. It's going to be interesting. If there's a conference call, it's going to be interesting to see what they say. All right. Let's get to a developing story now on Paramount. Sherry Redstone's national amusements deciding to stop deal talks with Skydance. David Faber. Come on.
12:39Come on. You can see with your own eyes. You know, before I know when I run it, when I saw David in the foyer, which I rarely do. What did I do? I was yelling David Faber's here. I was so excited on the phone. He was busy. I know. And much to his consternation, I did that. However, David, what's the latest? Thank you for that. Always always appreciate it. You know, I love you. Listen, you know, something of a shock late in the day here, Melissa, of course, as we reported and others have as well, that essentially the talks between Skydance, run by David Ellison, son of Larry Ellison, obviously playing right off of Oracle there as well, and their partner Redbird, the private equity firm, have ended.
13:19They had an offer out there, of course, that would have involved buying the control stake in Paramount through the purchase of National Amusements, the 77 percent of the shares of the voting shares that are in that entity, in addition to providing as much as liquidity for as much as 50 percent of the owned shares, the B shares and some of the other A's at a price of 15 for the B's and 23 for the A's that were not part of national amusements. Not going to happen. It's over. Six months of negotiation. Every expectation that they would figure out a way to get to the finish line is done. Why? Well, Sherry Redstone has decided against it, perhaps at the advice of some of her attorneys, perhaps some others as well.
14:05It's unclear exactly why, I guess, is what, you know, ultimately I've been reporting on this thing. This is just my recent file. This lasts a couple of weeks. You know, at the end of the day, some people say it was not about the economics. It was about other details, non-economic details. That may be the case. I go back, though, to the fact that while originally Redbird and Skydance were offering$2 billion to Sherry Redstone for national amusements. They reduced that to$1.7 billion when they increased the amount that they were going to be giving to the B shares. That made the special committee happier, perhaps, and their advisors, but it may have made Sherry Redstone somewhat unhappy, that reduction, even though I'm told it was coming back to her in other ways, including things like indemnifying her against potential litigation and the like.
14:52And so here we are. This is a company that does not have a CEO. It's run by three different people. It is under duress, of course, as much of the industry, at least in terms of where its position is and how it's trying to fight for relevance, really, in many ways. It's got an enormous debt load and it's very much unclear what the future holds for it, except that they seemingly have a plan to kind of continue as an independent company with Sherry Redstone's National Amusements, the control holder. Aren't there other options out there? You know, there are no other options for a deal in which paramount shareholders, as we described them, beholders, will get any money.
15:28Not that I'm aware of. There has been some reporting on Edgar Bronfman, perhaps trying to mount a bid for NAI and a couple of others as well. But that would be, as I understand it, for simply the control stake in NAI. By the way, that would bring on plenty of litigation of its own. The idea that there would be one beneficiary of said deal, whereas Paramount shareholders would see nothing. That was what the special committee was trying to sort of balance. Yeah, you get taken out at a more significant premium, but give us something. And they did get to a real point there. They got a lot from Skydance.
16:00And ultimately, it simply was not enough to convince Sherry Redstone, perhaps because they did lower her ultimate economic value just a couple of weeks ago when they came up to paying four and a half billion for that 50 percent of the B's and some of the A's that they were going to buy to premium. All right, David, you just mentioned that debt load. So a net debt is 2x its market cap now after today's decline. Right. It's around 12 billion, a little over that. Yeah. And so when you look at this thing, it does 30 billion dollars in revenue, but it's just on a gap basis. It's not profitable. How does this shake out if there are no buy?
16:31I mean, like and what does it say about like what comes next for some of these other streamers that are having a difficult time? Well, Paramount, you know, is in a difficult position, you could argue. I mean, they will say, obviously, Paramount Plus has had success. It continues to add subscribers. They have the NFL at CBS. They feel like that's an undervalued asset. But to your point, Dan, they have a lot of cable networks. And we know that that is a very difficult place to be right now, given the continued reduction overall of the cable ecosystem. Not to mention they have a convertible preferred out with Byron Trott's firm or the Michael Dell Byron Trott combination, whose initials I can never completely remember.
17:09There's a good so there's a good deal of indebtedness. There's also indebtedness at national amusements. I don't know is the answer. You'd have to believe that they're going to have to have one person running this company to begin with and then embark on whatever plan it is. Obviously, their former CEO, Bob Backish, left about a month or so ago. So it's a good question. I don't know what the future holds for this company. And there are many who believe it's going to be a very difficult road and thought that the Skydance deal and the liquidity it provided in the merger of Skydance Studio into the overall whole.
17:40And the plan that David Ellison, who runs Skydance, had been working on for many months was perhaps the best opportunity. So let me just ask you a question back to the art of the deal. So those terms seem to have been set some number of weeks ago. And so what is the nature then of why today? Why is it that those? You know, I mean, as somebody who knows a way around a deal, you know, I can't tell you specifically. First of all, let's not forget. She was the one. Sherry Redstone is the one who empowered a special committee in the first place. She said, I'm supportive of this potential transaction.
18:15Will you weigh in on it? That's the whole process began in part because she was supportive. I'm told over the last 10 days since perhaps that I don't want to call it a retrade, but since they lowered the overall value they were willing to pay, I am told that she seemed to sour on the deal. So maybe it was pure economics coming to her, you know, from two billion to one point seven billion. Maybe there were maybe she was having second thoughts in terms of just the emotional value of it, so to speak. It's been national amusement, certainly been in her family for a very long time. Paramount. That deal was done.
18:49Viacom was done, what, 1980, when her father Sumner bought that. I don't know is the answer. It's incredibly rare to see a deal like this collapse like this at the last moment. You would think you make the decision as to whether you want to sell first, not last. Right. Yeah. And I wonder what that back and forth was like. Yeah. Yeah. And I, you know, I'm trying to understand that specifically. Ropes and Gray is her attorney. Ellison was represented by Latham. I know there was a lot of friction there in terms of the back and forth. But really, as I followed this, Skydance and Redbird gave on virtually everything.
19:22The only data, the only thing they were not willing to give on was a majority of the minority vote. Otherwise, they gave them everything they wanted in terms of economics. So very much unclear why it would have come to this at the very end. David, always great to have you here on set. Thank you. Always good to be here, particularly with, you know, well, it's a Mount Rushmore. David Faber's pantheon. I mean, I don't know who the other three are. David's one of them. It makes me just feel really old. These guys are set in stone. You know that, right? They're iconic. They last forever. All right.
19:58Good to see you, David. Thanks. And you, Melissa. Coming up, all eyes on the Fed ahead of tomorrow's rate decision. What Chair Powell's comments will mean for markets and why our next guest is feeling positive ahead of the news. And check out these fast movers. Catching your attention, how the traders are navigating the action. Cleveland Cliffs, GM, and Bitcoin. Don't go anywhere. Fast Money's back in two.
20:23Welcome back to Fast Money. The S &P 500 and Nasdaq closing at record highs today while the Dow dropped 130 points as investors await tomorrow's CPI report and Fed decision. For more, let's bring in Stuart Kaiser, Citi's head of equity trading strategy. Stuart, great to see you. Thanks for having me. You say stick with the momentum in this market. It should keep going higher. Do you feel like embedded in that is really a call in NVIDIA? That's what it feels like these days. Yeah, I mean, look, the way the performance has been, it's hard for the equity market to work without large cap tech working.
20:52I mean, it's 30 percent of market cap and it's where the thematic and the kind of flows are. But, you know, our view is generally speaking, you run long equities until the labor market starts to show like real meaningful weakness. When that happens, you get out quick and you protect yourself. But we've been pretty resilient to the other data just on that kind of basic logic. What's the meaningful? It's interesting you say that. Is it going to happen? See, I thought last year you'd start to see a significant rise in unemployment. Didn't happen. We ticked 4%. The revisions month over have been bad now for the better part of a year and a half.
21:22What does that look like to you? Like, what number is that threshold? You know, it's a great question because if you look back to last year, we printed 105 on a revised basis in October. We had claims up to 260. I think you probably need payrolls sub-125K at least and claims above 250. So those are the types of levels where even though that's not recessionary, the market will start to extrapolate that out and kind of increase the risk that it happened. But something like that, it might even need to be sub 100K. What's interesting is you actually historically have more negative payroll prints than you have prints between zero and 100K.
21:52The market doesn't hang out between zero and 100. And I think that's why if you got to that level, the market is just going to start the price, the chance you kind of step off the curb a little bit. So, Stuart, when you look at the volatile food and energy that's pulled out, don't you want to see the food and energy now? Because they're actually lower in the last month or so. That might give a little tailwind to the deflationary aspect of that number. And where do you see the sell-off? If you do, on your ascent to your levels, where do you see the sell-off happening? It's a great question. I mean, right now you want to see the food and energy because it happens to be lower.
Read the full transcript
22:25Three months ago, we probably would have been having the opposite discussion. But the bottom line is the Fed is focused on core, you know, so we're going to focus on core. I think if you got weak payrolls or you look like you're getting recessionary data, you want to get short that domestically facing cyclical. So that's going to be your small caps, your banks, your retailers and things of that nature. So I think that's what people are targeting. I would say the two areas that people are most concerned about would be U.S. consumer because it's been labor market and consumer spending. And they're kind of in the white nights of the economy.
22:51So you need to see weakness there for a recession to really emerge. And the second would be anything that's kind of susceptible to higher for longer. So I think those are the two kind of weak spots. So in your view, so you're saying stay with the momentum. What's your what is your expectation for what the Fed does? Look, tomorrow, we're pretty positive on tomorrow. Our economists have like 20. Positive means you think they lower? We think positive, no positive for equities. So we think it'll be a positive catalyst for equity markets. And the logic being core CPI, we have 26 basis points and our economists have directly flagged downside risk to that number.
23:21Generally speaking, Powell has kind of skewed more dovish than the committee itself. So you'd assume the press conference, to the extent he can be, will kind of drift a little bit dovish. Friday probably limits that a little bit. You know, when you put that wage inflation where it was, when you print such a strong payrolls number, they can't go outright dovish. But, you know, the view is that there is a risk to the downside on inflation, which should be good for equities. And the Fed itself could could tilt a little dovish. The risk there would be the revisions to their economic projections. They're probably going to take up the inflation assumption within there.
23:51So there might be a little risk around that. But otherwise, you know, as the economy goes, go equities, and that data continues to come in pretty good. So there was a better-than-expected 10-year auction. And I'm wondering if you think, do you have any sort of conspiracy theory embedded in that, in that, you know, maybe traders are sniffing out, like, softer CPI, and so Fed goes dovish, you know, the cuts get pulled forward? You know, it could be. Our inflation traders think there's actually a pretty tight expectation around core CPI tomorrow. We had a call this morning and they had it between like 24 and 28 basis points.
24:23So the market seems fairly confident that we're going to get a solid to slightly low print. So that could that could explain part of the auction. That does kind of open up some risk reward, though. I mean, when everybody's kind of coalescing around a positive outcome, you definitely definitely need to kind of monitor that and keep and keep an eye on it. The auctions in general have been a bigger focus for equity markets the last six to nine months than they have been probably for any time in the last 20 years. So seeing good news on that, equity folks are probably going to say, oh, the bond market knows more than us anyway.
24:50So if that went well, then we might as well just keep buying stocks. All right, Stuart, great to see you. Thank you, Stuart Kaiser. What do you think, Dan? To use an expression that Guy likes to use, it seems like a lot of investors are really focused on Goldilocks situation. I've never used that term ever on this show. Gobble, gobble. See, they're just saying. No, no, but all right. So Guy doesn't use that. So, you know, weaker data means greater probability of rate cuts and stronger data. You know, we're still just doing fine higher for longer. Risk assets have done pretty well. The economy keeps chugging along.
25:23And I just think that probably there's got to be something in between that. We really haven't had any fear put in the market. It's been over, you know, a year since we've had a down 2 % day in the SPX. You know, and you think about we haven't even had a 10 % sell off since SVB, you know, a year and a half ago. So it just seems there's a lot of complacency right here. OK, there is a lot more fast money to come. Here's what's coming up next. Cars, crypto and Cleveland Cliffs. The traders are tackling more of today's big movers and weighing in on whether any of them can boost your portfolio. Plus, sizing up the competition.
25:59How one pharma company is trying to take on the weight loss heavyweights. The CEO of Structured Therapeutics joins us first on CNBC to lay out how they're stacking up. You're watching Fast Money live from the Nasdaq market site in Times Square. We're back right after this.
26:21Welcome back to Fast Money. Some fast movers on our radar today. GM announcing a new$6 billion stock repurchase program as the automaker's$10 billion buyback announced in November is expected to finish by the end of the month. GM is also cutting its EV production forecast. Shares of Cleveland Cliffs getting hit after a downgrade at J.P. Morgan analysts citing weakening fundamentals and rising CapEx needs. That stock now down more than 26 percent this year. And regional and money center banks both tumbling today on a warning from PIMCO. According to Bloomberg, the investment firm saying that more trouble is ahead for the commercial real estate sector.
26:57PNC also had a Morgan Stanley conference today talking about office loans, working through office loans, and that charge offs will be coming. So perhaps some concerns still about the regional bank exposure to CRE. What did we play that game the other day? We play lots of games. No, no, but we did it the other woods today. Maybe it was last week. Traded or faded? Would you rather? No, no, no. Most important chart of the week. Remember that whole thing, right? That's not a game, though. But go ahead. Well, it's whatever it is. But I think Karen had a great one. Remember, she won. You said she won.
27:22Oh, NVIDIA. Of course. But I said I thought KRE was a good one. You said not really. But as it turns out, maybe it is. But if I had put it up, you would have said, oh, my God. That's a great one. Oh, for sure. It could be on a big board outside. I think, listen, I still think there's something clearly going on with these mid-cap and small banks in the form of the KRE, which on valuation is compelling, but they don't trade particularly well. And I think to a certain extent, some of the large cap banks today, the weakness might have been predicated on that. Well, part of the PIMCO article, the Bloomberg article about PIMCO is the head of CRE within PIMCO saying that larger banks were getting rid of some of their weaker loans in anticipation of something bigger happening.
28:03Right. And just not wanting to have them. They can write them down. But, you know, just looking at the exposure of the bigger banks, it's really very small. And I'm sure that if we are in a moment of upheaval again and you have regional banks failing, the whole sector will trade down. However, that provided huge opportunities for all of the big money center banks. Coming up, the obesity drug race rages on. Instructor Therapeutics is aiming to size up as oral GLP-1s gain momentum. CEO Ray Stevens joins us next to detail the company's new data and the$100 billion market opportunity in the space.
28:38The details when Fast Money returns. Missed a moment of fast? Catch us anytime on the go. Follow the Fast Money podcast. We're back right after this.
28:57Welcome back to Fast Money. Structure Therapeutics down more than 5 % today, but shares are still holding on to a near 50 % gain since the biotech company released early stage data on its small molecule GLP-1 pill last week. Patients losing an average 6.2 % of their body weight after 12 weeks on the orally ingested drug. That's comparable to Lilly's GLP pill in trial, potentially setting up structure as a heavy hitter in the weight loss drug boom. Joining us now in a first on CNBC interview, Structure Therapeutics CEO Ray Stevens. Ray, great to have you on the show. Thank you very much for having me on the show, Melissa.
29:30I'm excited to be here to talk about Structure Therapeutics and the data we released last week. How are you thinking of the niche that this oral pill will fill? On the conference call that you had with analysts, it sounded like you're positioning it as a direct competitor to the oral offerings that Lilly is currently researching, Novo is currently researching. But then there is also some indication that you would be entering a trial of it being a maintenance drug. How should we think of it? Yeah, absolutely. So, you know, the drug that we've created called GSBR 1290, this is what we call an oral small molecule.
30:04So you should think about ibuprofen, Advil, Lipitor, your blood pressure lowering medication. So these are small molecules. And the reason why I emphasize that point is one of the advantages small molecules have is we have the ability to scale so we can make enough material for more than 100 million people. Today, or in 2023, only 5 million people were able to get access in the United States alone. And so the scaling is really, really important. Secondly, in terms of positioning, we look at this as the data that we shared last week was between 6.2 % and 6.9%. And so we think that is as competitive.
30:45And we had additional data that showed even better. So we think that we have a potentially best in class in terms of efficacy. see. And that, combined with the very low discontinuation rate, combined with the ability to scale this to large numbers that need it, we think we're in a very good competitive position. So will this be the drug that people will take initially to initiate that weight loss, in addition to potentially taking it to manage weight loss? Or are you thinking this is potentially, you know, after people do the injectable, they use this as a maintenance drug? I'm just trying to think of how you're thinking of your total addressable market.
31:22Yeah, Melissa, and I've heard you say on the show before, you know, the potential we call maintenance phase. So there's two phases. You know, individuals, participants initially will go on what we call the titration phase. Your body's not used to taking these drugs. You have a lot of things that are changing. Your gastric emptying is slowing down. And so we have this induction or titration phase that's initially done. And then once you finish that, you then go on what we call the maintenance phase, which is longer term, thinking for many, many years. One obvious place that I've heard you mention before is the maintenance phase.
31:56And clearly, oral small molecules, an oral pill, our physicians tell us their patients, they want to get up in the morning, they want to take their pill, drink their coffee, and go to work. So it's very well suited for the maintenance phase. But we think primary physicians, they will also prefer just immediately going to the oral pill option. So really, both options exist. people that are already on one of the injectables, they can stay on that. They've already gone through the titration, the induction phase, and they can go right on to the oral pill for maintenance. But those that are new, they might want to start right away on an oral pill.
32:34We heard from Lily just yesterday that it's phase three readout on its oral formulation will take place April 2025. That's what they're projecting right now. What is the next key date for your compound, and how quickly can you then get it to market? Yeah, it's a great question. So we will, one of our next key data points is we'll be initiating our phase 2B study. This is a 300 participant study. We'll be initiating that in Q4 of this year with the data readout at the end of next year. So that's one key milestone. The way that we look at this is, you know, Eli Lilly is clearly, you know, first to market with an oral pill.
33:17And we actually view this as an advantage. We're able to learn a tremendous amount by having them be ahead of us. What's most important to us isn't to be first in class, it's to be best in class. And if you think about the story of the statins, you know, it was Mevacor that was first in class in 1987 for cholesterol lowering and improving cardiovascular risk. But it wasn't until about 10 years later that Lipitor from Park Davis came along and that got the real lion's share of the statin market. And that was, you know, I think 2006 peak sales at over 12 billion. So we see ourselves as, you know, we see the parallels with the statin story, only this is a much bigger market than the statins.
33:58You also indicated in your conference call they've already manufactured a great deal of the product under good manufacturing practices. So does this mean that you have the ability and the funding to actually go to market and manufacture this? You have the capability already. How should we be thinking about that part of the equation? Yeah. So when we designed this, we knew GLP-1s and the Novo Nordisk and Lilly, they're pioneers in the field. They've been trailblazers with the injectable peptides. But we've always known they can't scale that to the level that's needed globally. Or in the United States, 100 million people need this medicine, just like the statins.
34:35Globally, it's 800 million people. And so from the very beginning, when we designed the molecule, we thought about scalability. And so when we made the molecule, we had that front and center. With that in mind, we're able to scale up to right now, we have the capability to go to 6 ,000 metric tons. That's enough material for more than 120 million patients today. And so we think that puts us in a good position for having multiple avenues. And that's not even talking about combination drugs. You hear a lot about GLP-1, GIP, GLP-1 amylin. We think that, you know, GSBR-1290 or the GLP-1s, they're kind of the foundation, but they're almost certainly going to be used in combination with other drugs.
35:17So there'll be even an even bigger need down the road. Last quick question, Ray. Are you for sale?
35:26You know, Melissa, one thing that we've always said from the beginning, this market is just too big for us to commercialize ourselves. We know that. And what drives us, our passion, what we have above our kitchen sink in the office is making medicines accessible to all. And so commercialization, we know that we're going to need a partner for that. Right now, we're just focused on making sure that we can develop this drug as quickly, as efficiently, and safely as possible to get this to market. And then commercialization, we think we need a partner to really be most successful in accessibility.
35:58Okay. Ray, we'll leave it there. We hope you'll come on the show again. Thanks for your time. Thank you very much. I appreciate it, Melissa. Ray Stevens, CEO of Structure Therapeutics. Sound like a yes. Well, partnerships is interpretable, but we'll see. After the break, more headwinds for Boeing shareholders, the disappointing delivery numbers that sent shares reeling today and the impact on the broader transport trade. Next, Fast Money's back in two.
36:29Welcome back to Fast Money. Boeing shares dropping today after the aerospace giant announced it delivered 24 commercial aircraft in May, less than half of the 50 delivered in the same month a year ago. Boeing has reduced 737 max production in order to improve manufacturing quality following a series of accidents. Meanwhile, Boeing's main rival, Airbus, announced it delivered 53 commercial jets in May, bringing its total to 256 on the year. Who's positive Boeing, Guy? I am, but I'm probably one of the few people, and it's been right not to be. But I'll say this. I mean, I think they report at the end of, I want to say, July 24th.
37:03So you got some time, number one. All the, I mean, devastating news has been out in the stock. And their defense, and we've talked about this, their defense business is being valued at basically, effectively, you know, nothing. I mean, that's a bit of an exaggeration. But my point is, it is not getting its just due. And if they can just get out of their own way, which I think they will, I mean, this stock should be back somewhere between 215 and 230. It's not unfeasible to think that. I understand how horrible it looks now, but I don't think you should run away from Boeing here. So I'm conflicted on this one because if it weren't a duopoly, and I've said this a bunch of times, if it weren't a duopoly, this stock should be trading at$50, maybe lower, right?
37:42There's no way to tell what it should be valued at. But Airbus is eating their lunch. Not only do they need another CEO, but they're going to have to figure out what they're going to do with the plane. Are they going to totally scrap the plane? Are they going to make another plane? What are they going to do at this point? Any way you slice it, it's more money. So you can't invest in it until I know the plan. And we're not going to know the plan for another six months or so. All right. Coming up, we are clawing into GameStop options as Roaring Kitty's supposed options position year's expiration.
38:10What the decline in that stock could mean for the meme traders' millions? More Fast Money in two.
38:23Welcome back to Fast Money, a rollercoaster ride for GameStop shares today, with the stock closing up 22 percent after falling more than 8 percent in early trade. Shares still down 35 percent in the last three days, though, after Roaring Kitty's live stream on Friday. But what is going on with his options bet? But Baycrest Managing Director David Buhl joins us now to break down the action. David, what do you think? Well, it's always interesting in GameStop stock and GameStop options. Like you said, the stock was up 20 percent today. This falls on the heels of multiple 40 plus percent moves last week.
38:58And so when I'm looking at GameStop options, the June options are pricing in about a 20 percent move every day. So these are actually normal moves based on the way the options are priced. Now, of course, there is heavy open interest in the YOLO type calls, the very far out of the money calls. Those are incredibly expensive, even more expensive this time around than in January of 2021. But this up 20 percent, down 20 percent moves we're seeing are about normal based on the way the options are priced there right now. Hey, David. So last night, Keith Gill disclosed his positions, 120 ,000 of the June.
39:35Next Friday, expiration, 20 strike calls, paid about 585 for that. So the stock is 30 and change. So they're basically trading like stock. You advise a lot of institutional clients with positions like this. What would you suggest he should do eight trading days out? Because again, like you said, there's a lot of volatility. There's a whole host of things that could kind of have this stock go back towards that$20 strike. So as you mentioned, he controls apparently 120 ,000 of these calls, which are equivalent to 12 million shares of Notional, add that on to another 5 million shares, that's 17 million shares.
40:11That's essentially trading like stock that he controls 17 million shares of right now. And so contrary to some of the takes that I've seen on Twitter, the market makers on the other side of these call positions, they're already long some 10 million, 11 million share equivalents. So there's not going to be some phantom stock that needs to be created if he does go ahead and exercise those calls from how I see it. Where I do see some institutional investors finding some opportunities on the modest upside. Those very far up 50 percent, up 100 percent out of the money calls are priced so expensively that the up 20 percent, which is a modest move for GameStop range of that part of that distribution, is priced very attractively.
40:53And I'm seeing some investors take some bets there. Wow. David, thank you. David Bull. Thanks, Adam. I'm surprised every day that this stock goes up by this much and continues to do so. The story doesn't go away. I mean, if I'm games, first of all, they did, what did they do, Karen? A 75, I want to say. Yeah, well, they had already done some. And they did more. They did 45 million a few weeks ago. Right. And they had another 30 million. Which is good for them. But how do you think they feel their stock is now just a carnet? It's a sideshow. It's got nothing to do with their business. I mean, that would be, for me at least, a little bit disappointing that your company is no longer a company.
41:31It's just basically a point of speculation for a lot of people out there. If it gives you another lifeline or two, I don't care. If you own the stock and it goes higher, you don't care either. It's becoming a trading vehicle. It's not becoming. It is a trading vehicle. And sooner or later, they'll invest in something or they'll die. All right. Up next, final trades.
42:04Time now for the final trade. Steve Grassley. We're going to need more data centers. Do you know what we need with more data centers? It's right up there on the screen. Micron. Karen. You know, I liked it last week, and I've owned it for a while, Citibank. And, you know, today this was just overdone to the downside. Still like it. Let her see. Dan, Nathan. We've got some time, don't we? Yeah, we do. So it's interesting. Remember that Internet bubble like 25 years ago? Yeah. The two of the names that have just sat out this whole generative, and it's pretty close to what's going on here to then, is Cisco and Intel.
42:37They can't get out of their own way, but I think they're going to join the party at some point. So you like them? Yeah. They led the bubble. Hold on. So bad they're good. Nice. Guy. Is David Faber in your Mount Rushmore? Don't answer that. It's very hard because he's in mine, and I don't care if anybody gets mad. Palo Alto Network. while turning back higher. Thanks for watching Fast Money. Mad Money with Jim Cramer starts right now. All opinions expressed by the Fast Money participants are solely their opinions and do not reflect the opinions of CNBC, NBC Universal, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet, or another medium.
43:16You should not treat any opinion expressed on this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion. Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such. To view the full Fast Money disclaimer, please visit cnbc.com forward slash fastmoneydisclaimer.
From the publisher
Shares of Apple jumping to record highs just a day after falling flat on its new AI announcements. The turnaround for the tech titan, and what it means for the market. Plus The weight loss wars rage on… and we’re honing in on oral version of GLP-1’s. How one pharma stock is faring in the space, and how their results stack up against the competition.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
